Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Union Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The AI regimen is a combination chemotherapy treatment consisting of doxorubicin (Adriamycin) and ifosfamide, primarily used for the treatment of soft tissue sarcomas. Doxorubicin is an anthracycline antibiotic that exerts its antineoplastic effect by intercalating between DNA base pairs and inhibiting topoisomerase II, leading to DNA strand breaks and inhibition of macromolecular synthesis. Ifosfamide is a nitrogen mustard alkylating agent that requires metabolic activation to form DNA-reactive species that cross-link DNA strands, thereby interfering with DNA replication and transcription. Fujian Medical University Union Hospital is investigating this regimen in a Phase 2 clinical trial as part of a total neoadjuvant therapy approach, combined with hypofractionated radiotherapy, for patients with localized extremity soft tissue sarcomas.
- Brand names
- Adriamycin
- Other names
- Adriamycin + ifosfamidedoxorubicin and ifosfamide
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + ifosfamide.